Effect of a novel tetrapeptide derivative in a model of isoproterenol induced myocardial necrosis

被引:17
作者
Ramesh, CV
Malarvannan, P
Jayakumar, R
Jayasundar, S
Puvanakrishnan, R [1 ]
机构
[1] Cent Leather Res Inst, Dept Biotechnol, Madras 600020, Tamil Nadu, India
[2] Tamil Nadu Vet & Anim Sci Univ, Dept Pharmacol & Toxicol, Madras Vet Coll, Madras, Tamil Nadu, India
[3] Cent Leather Res Inst, Bioorgan Lab, Madras 600020, Tamil Nadu, India
关键词
myocardial necrosis; isoproterenol HCl; tetrapeptide; cardioprotective effect;
D O I
10.1023/A:1006835526608
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Isoproterenol hydrochloride (ISO), a beta adrenergic agonist, is known to cause ischemic necrosis in rats. Cardiotoxicity of three different doses of ISO were studied using physiological, biochemical and histopathological parameters. The effects of single and double dose of ISO were analysed, which illustrated that single ISO dose was more cardiotoxic than double ISO dose due to ischemic preconditioning. The tetrapeptide derivatives L-lysine-L-arginine-L-aspartic acid-l-serine (tetrapeptide A) and di-tert.butyloxycarbonyl-L-lysine-L-arginine-L-aspartic acid-tert.butyl O-tert.butyl-L-serinate (tetrapeptide B) along with acetylsalicylic acid as positive control were analysed at different time points for their cardioprotective effect. The results demonstrated that optimal protective effects were observed by pretreatment with 5 mg/kg of tetrapeptide B and this was found to be slightly better than that of acetylsalicylic acid. A lesser degree of cardioprotection was noticed when low doses of tetrapeptide B were administered. This study clearly showed that single dose of ISO (50 mg/kg, s.c.) induced myocardial necrosis could be used as a model to assess cardiovascular drugs and in this model, it was demonstrated that the tetrapeptide B could exhibit optimal cardioprotective effect.
引用
收藏
页码:173 / 182
页数:10
相关论文
共 33 条
[1]   NAFAZATROM-INDUCED SALVAGE OF ISCHEMIC MYOCARDIUM IN ANESTHETIZED DOGS IS MEDIATED THROUGH INHIBITION OF NEUTROPHIL FUNCTION [J].
BEDNAR, M ;
SMITH, B ;
PINTO, A ;
MULLANE, KM .
CIRCULATION RESEARCH, 1985, 57 (01) :131-141
[2]  
BESBASI FS, 1990, AM J VET RES, V51, P36
[3]  
Cao A. P., 1994, PHARMACOL TOXICOL, V74, P321
[4]  
CHAPPEL CI, 1959, ARCH INT PHARMACOD T, V122, P123
[5]  
DAVIES MJ, 1977, J CLIN PATHOLOGY S11, V30, P45
[6]  
DROUET L, 1990, NOUV REV FR HEMATOL, V32, P59
[7]   NOVEL ANTIPLATELET THERAPIES FOR TREATMENT OF PATIENTS WITH ISCHEMIC-HEART-DISEASE - INHIBITORS OF THE PLATELET GLYCOPROTEIN IIB/IIIA INTEGRIN RECEPTOR [J].
FRISHMAN, WH ;
BURNS, B ;
ATAC, B ;
ALTURK, N ;
ALTAJAR, B ;
LERRICK, K .
AMERICAN HEART JOURNAL, 1995, 130 (04) :877-892
[8]   INTRAVASCULAR PLATELET AGGREGATION IN HEART INDUCED BY NOREPINEPHRINE - MICROSCOPIC STUDIES [J].
HAFT, JI ;
ALBERT, FJ ;
FANI, K ;
KRANZ, PD .
CIRCULATION, 1972, 46 (04) :698-&
[9]  
HANDIN RI, 1994, HARRISONS PRINCIPLES, P1810
[10]   CURRENT AND FUTURE PERSPECTIVES ON ANTITHROMBOTIC THERAPY OF ACUTE MYOCARDIAL-INFARCTION [J].
HENNEKENS, CH ;
ODONNELL, CJ ;
RIDKER, PM .
EUROPEAN HEART JOURNAL, 1995, 16 :2-9